Note 3 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Revenue from Contract with Customer, Including Assessed Tax	$ 2,083	$ 0
Reserves for Sales Returns and Consumer and Trade Promotion Obligations	1,000		$ 1,300
Advertising Expense	9,600
VAZALORE [Member]
Revenue from Contract with Customer, Including Assessed Tax	2,100
VAZALORE 81 mg Dose [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 1,700
VAZALORE 81 mg Dose [Member] | Product Concentration Risk [Member] | Revenue, Product and Service Benchmark [Member]
Concentration Risk, Percentage	79.00%
VAZALORE 325 mg Dose [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 400
VAZALORE 325 mg Dose [Member] | Product Concentration Risk [Member] | Revenue, Product and Service Benchmark [Member]
Concentration Risk, Percentage	21.00%